Polygenic hazard score to guide screening for aggressive - prostate cancer: development and validation in large scale - cohorts

dc.contributor.authorTyler M Seibert
dc.contributor.authorChun Chieh Fan
dc.contributor.authorYunpeng Wang
dc.contributor.authorVerena Zuber
dc.contributor.authorRoshan Karunamuni
dc.contributor.authorJ Kellogg Parsons
dc.contributor.authorRosalind A Eeles
dc.contributor.authorDouglas F Easton
dc.contributor.authorZSofia Kote-Jarai
dc.contributor.authorAli Amin Al Olama
dc.contributor.authorSara Benlloch Garcia
dc.contributor.authorKenneth Muir
dc.contributor.authorHenrik Grönberg
dc.contributor.authorFredrik Wiklund
dc.contributor.authorMarkus Aly
dc.contributor.authorJohanna Schleutker
dc.contributor.authorCsilla Sipeky
dc.contributor.authorTeuvo LJ Tammela
dc.contributor.authorBørge G Nordestgaard
dc.contributor.authorSune F Nielsen
dc.contributor.authorMaren Weischer
dc.contributor.authorRasmus Bisbjerg
dc.contributor.authorM Andreas Røder
dc.contributor.authorPeter Iversen
dc.contributor.authorTim J Key
dc.contributor.authorRuth C Travis
dc.contributor.authorDavid E Neal
dc.contributor.authorJenny L Donovan
dc.contributor.authorFreddie C Hamdy
dc.contributor.authorPaul Pharoah
dc.contributor.authorNora Pashayan
dc.contributor.authorKay-Tee Khaw
dc.contributor.authorChristiane Maier
dc.contributor.authorWalther Vogel
dc.contributor.authorManuel Luedeke
dc.contributor.authorKathleen Herkommer
dc.contributor.authorAdam S Kibel
dc.contributor.authorCezary Cybulski
dc.contributor.authorDominika Wokolorczyk
dc.contributor.authorWojciech Kluzniak
dc.contributor.authorLisa Cannon-Albright
dc.contributor.authorHermann Brenner
dc.contributor.authorKatarina Cuk
dc.contributor.authorKai-Uwe Saum
dc.contributor.authorJong Y Park
dc.contributor.authorThomas A Sellers
dc.contributor.authorChavdar Slavov
dc.contributor.authorRadka Kaneva
dc.contributor.authorVanio Mitev
dc.contributor.authorJyotsna Batra
dc.contributor.authorJudith A Clements
dc.contributor.authorAmanda Spurdle
dc.contributor.authorManuel R Teixeira
dc.contributor.authorPaula Paulo
dc.contributor.authorSofia Maia
dc.contributor.authorHardev Pandha
dc.contributor.authorAgnieszka Michael
dc.contributor.authorAndrzej Kierzek
dc.contributor.authorDavid S Karow
dc.contributor.authorIan G Mills
dc.contributor.authorOle A Andreassen
dc.contributor.authorAnders M Dale
dc.contributor.authorThe PRACTICAL Consortium
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id30040432
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/30040432
dc.date.accessioned2022-10-28T13:59:15Z
dc.date.available2022-10-28T13:59:15Z
dc.description.abstractOBJECTIVESTo develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.DESIGNAnalysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score >= 7, stage T3-T4, PSA (prostate specific antigen) concentration >= 10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa.SETTINGMultiple institutions that were members of international PRACTICAL consortium.PARTICIPANTSAll consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men.MAIN OUTCOME MEASURESPrediction with hazard score of age of onset of aggressive cancer in validation set.RESULTSIn the independent validation set, the hazard score calculated from 54 single nucleotide polymorphisms was a highly significant predictor of age at diagnosis of aggressive cancer (z= 11.2, P< 10(-16)). When men in the validation set with high scores (>98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P= 0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score.CONCLUSIONSPolygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa.
dc.identifier.jour-issn0959-8138
dc.identifier.olddbid185614
dc.identifier.oldhandle10024/168708
dc.identifier.urihttps://www.utupub.fi/handle/11111/42358
dc.identifier.urnURN:NBN:fi-fe2021042718839
dc.language.isoen
dc.okm.affiliatedauthorSchleutker, Johanna
dc.okm.affiliatedauthorSipeky, Csilla
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherBMJ PUBLISHING GROUP
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumberj5757
dc.relation.doi10.1136/bmj.j5757
dc.relation.ispartofjournalBMJ
dc.relation.volume360
dc.source.identifierhttps://www.utupub.fi/handle/10024/168708
dc.titlePolygenic hazard score to guide screening for aggressive - prostate cancer: development and validation in large scale - cohorts
dc.year.issued2018

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
bmj.j5757.full.pdf
Size:
471.38 KB
Format:
Adobe Portable Document Format
Description:
Publisher's version